Comments
Jubilant Life Sciences subsidiary has signed long-term contracts in the US for the supply of some of its diagnostic and therapeutic products.
In a BSE filing, Jubilant Life Sciences today said: “Its wholly-owned subsidiary Jubilant Pharma, through one of its units, Jubilant DraxImage Montreal Canada (JDI), has signed long-term contracts with distribution networks in the US for supply of products used for diagnostic and therapeutic procedures for thyroid, myocardial perfusion, lungs, kidney and bone scans to be supplied by JDI over 39 months effective January 2017.”
Chairman Shyam S Bhartia and Hari S Bhartia, co-Chairman and MD, Jubilant Life Sciences, said: “These contracts provide visibility on our future revenues with differentiated and niche products in our speciality pharma business and will strengthen the company for its growth, going forward.”
The stock was trading 4.30 per cent higher at Rs 665.25 on the BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.